000950 重药控股
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入19,624,2830.02%80,119,10767,829,01062,520,75545,219,571
减:营业总成本19,384,5770.54%79,031,58066,608,40261,148,24544,064,665
    其中:营业成本18,103,4700.60%73,810,39362,008,78056,782,32940,985,178
               财务费用257,834-21.51%1,302,0281,094,2351,087,649701,598
               资产减值损失(99)-96.92%(27,756)(39,943)(12,883)(8,912)
公允价值变动收益9,6181,098.81%16,1622,318126,88317,452
投资收益86,71924.72%301,548293,349302,690287,978
    其中:对联营企业和合营企业的投资收益86,71927.71%291,454286,195279,408284,769
营业利润173,134-37.22%1,007,0951,435,0111,560,9271,371,385
利润总额174,736-39.24%1,008,5411,472,4901,580,2861,374,461
减:所得税费用39,974-28.42%236,042309,496289,613227,070
净利润134,763-41.85%772,4991,162,9951,290,6731,147,391
减:非控股权益31,802-51.61%117,542210,719285,229263,046
股东净利润102,961-37.99%654,957952,2761,005,444884,344

市场价值指针
每股收益 (元) *0.060-40.00%0.3800.5500.5800.510
每股派息 (元) *----0.0500.0600.105--
每股净资产 (元) *6.5675.83%6.5076.1105.6335.113
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容